Test Price
2,800 AED✅ Home Collection Available
KCNQ3 Gene Benign Neonatal Seizures Type 2 Genetic Test in UAE | 2,800 AED | DHA-Certified
Executive Summary & Core Metrics
Executive Summary
This advanced genetic test uses Next‑Generation Sequencing (NGS) delivered through an ISO 9001:2015 accredited laboratory, achieving 99.9% diagnostic sensitivity for the KCNQ3 gene. Premium VIP mobile phlebotomy and temperature‑controlled cold‑chain home collection are available daily from 8 AM to 11 PM. A compulsory pre‑test genetic counselling session is included, and post‑result telephonic clinical guidance is provided by a DHA‑licensed Consultant Medical Geneticist. Direct billing verification via WhatsApp at +971 54 548 8731.
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing & NGS validation.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (8 AM–11 PM).
- Clinical Guidance: Post‑test Telephonic Clinical Guidance by a DHA‑licensed Consultant Medical Geneticist.
- Insurance: Direct Billing Verification via WhatsApp at +971 54 548 8731.
Test Overview & Methodology
Comprehensive NGS Analysis of the KCNQ3 Gene
The test analyzes all coding exons and splice‑site regions of the KCNQ3 gene using next‑generation sequencing to confirm benign familial neonatal seizures type 2 (BFNS2). This potassium channelopathy presents as self‑limiting seizures in otherwise healthy newborns within the first days of life. Results are delivered in 3–4 weeks with 99.9% diagnostic sensitivity, enabling targeted therapy and accurate genetic counselling for families.
Primary Referring Specialists: Consultant Neurologist (Epileptologist), Consultant Neonatologist, Clinical Geneticist / Medical Researcher.
| Feature | Our NGS Test | Closest Alternative (Sanger Sequencing) |
|---|---|---|
| Methodology | Full NGS of KCNQ3 gene (all exons, ±20 bp intronic boundaries) | Single‑gene Sanger sequencing (lower throughput) |
| Diagnostic Sensitivity | 99.9% for point mutations and small indels | ~98% (limited to known mutations) |
| Turnaround Time | 3–4 weeks | 4–6 weeks |
| Sample Types | Whole blood, extracted DNA, or FTA card (one drop) | Whole blood only |
| Reporting | ACMG‑compliant classification + clinical annotation | Basic variant description |
Physician Insight & Safety Protocols
“As a Consultant Medical Geneticist with extensive experience in paediatric neurological disorders, I see this test as a cornerstone for early diagnosis of benign neonatal seizures. Identifying the KCNQ3 mutation not only stops the search for other causes but also brings clarity and reassurance to families. Our team ensures comprehensive pre‑test counselling and supports you in understanding the implications.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Medication Warning
Do not discontinue any prescribed anti‑seizure medication without consulting your doctor. Sudden withdrawal can precipitate life‑threatening status epilepticus. Always follow your neurologist’s advice.
Patient Safety Exclusion Criteria & Emergency Red Flags
- Exclusion Criteria: Inability to provide informed consent from a legal guardian (mandatory for minors). Unstable clinical condition requiring immediate NICU intervention before genetic sampling.
- Emergency Red Flags – Seek Immediate Medical Attention If: Seizure lasts longer than 5 minutes; baby develops fever, breathing difficulty, or cyanosis; new‑onset lethargy or poor feeding after a seizure.
Patient FAQ & Clinical Guidance
1. What is the KCNQ3 gene test and why is it needed for my newborn?
The KCNQ3 gene test uses Next‑Generation Sequencing to detect mutations causing benign neonatal seizures type 2, a condition where babies develop brief, self‑limiting seizures in the first days of life. Identifying the mutation confirms the diagnosis, avoids unnecessary investigations, and enables accurate genetic counselling for future pregnancies.
2. How accurate is this DNA test and can it miss a mutation?
With a diagnostic sensitivity of 99.9% for point mutations and small insertions/deletions, the NGS test is exceptionally reliable for the KCNQ3 gene; however, rare deep intronic variants or large deletions may require complementary methods. Our laboratory reports all findings according to ACMG guidelines, and a negative result reduces but does not absolutely exclude the possibility of another genetic epilepsy.
3. Will my insurance cover the 2,800 AED cost for the KCNQ3 test in the UAE?
Many UAE insurance plans, including those under DHA and Thiqa, cover medically indicated genetic testing when pre‑authorized; our team provides direct billing verification via WhatsApp at +971 54 548 8731 before your appointment. In cases of partial coverage, a nominal co‑payment may apply, and we offer flexible payment options.
4. How should I prepare my newborn for the sample collection?
No special preparation or fasting is needed for the infant. A genetic counselling session is required beforehand to draw a pedigree and review clinical history. Sample collection is by blood draw or a single drop on an FTA card – our mobile phlebotomist will use a temperature‑controlled kit.
UAE Regulatory & Data Privacy Adherence
Regulatory Compliance
This test is performed under the governance of the Dubai Health Authority (DHA). All patient data is handled in accordance with Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and patient consent adhere to Federal Decree‑Law No. 4 of 2016 on Medical Liability. The laboratory holds ISO 9001:2015 certification.
Clinical & Logistical Metadata
| Test Name | KCNQ3 Gene – Benign Neonatal Seizures Type 2 (BFNS2) Genetic Test (NGS) |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 weeks |
| Sample Type / Matrix | Whole blood, extracted DNA, or FTA card – VIP Mobile Phlebotomy & Cold‑Chain Home Collection available (8 AM–11 PM) |
| Methodology Used | Next‑Generation Sequencing (NGS) – Full gene sequencing with CNV detection |
| ICD-10-CM Code | G40.3 (Generalized idiopathic epilepsy and epileptic syndromes) |
| LOINC Code | 81319-0 (KCNQ3 gene sequencing) |
| DHA Facility License & Laboratory Address | DHA License: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians